BBNX
Beta Bionics, Inc.
BBNX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BBNX overall, supported by lower modeled downside and stronger fundamentals.
BBNX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BBNX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BBNX PE Valuation
BBNX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BBNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BBNX's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BBNX on the outlook, with more favorable earnings expectations.
BBNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.70 | +$0.37 |
| Q2 2026 | -$1.51 | +$0.46 |
| Q1 2026 | -$1.37 | +$0.55 |
| Q4 2025 | -$1.81 | -$0.53 |
| Q3 2025 | -$2.07 | -$0.77 |
| Q2 2025 | -$1.97 | -$0.70 |
BBNX is still losing money, but less than at its worst: $1.70 per share over the past year, against $2.07 at its worst in late 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BBNX on earnings quality, reporting a profit while its opponent remains loss making.
BBNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.5M | +30% |
| Q2 2026 | $32M | +38% |
| Q1 2026 | $27.6M | +57% |
| Q4 2025 | $32.1M | +57% |
| Q3 2025 | $27.3M | +63% |
| Q2 2025 | $23.2M | +54% |
| Q1 2025 | $17.6M | +36% |
| Q4 2024 | $20.4M | +145% |
BBNX has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | -12 points |
| Q2 2026 | -80% | +5.6 points |
| Q1 2026 | -88% | +18 points |
| Q4 2025 | -50% | +14 points |
| Q3 2025 | -63% | +3.2 points |
| Q2 2025 | -86% | -7.2 points |
| Q1 2025 | -106% | -33 points |
| Q4 2024 | -64% | +36 points |
BBNX's operating margin was −75% last quarter, down 12 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BBNX on profitability, with a higher operating margin.
BBNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$14.6M | -$4.6M |
| Q2 2026 | -$15.7M | -$288K |
| Q1 2026 | -$25.2M | -$4.9M |
| Q4 2025 | -$10.5M | +$4.3M |
| Q3 2025 | -$10M | +$1.5M |
| Q2 2025 | -$15.4M | -$2.6M |
| Q1 2025 | -$20.3M | -$7.8M |
| Q4 2024 | -$14.8M | -$8.2M |
BBNX has burned cash in almost every quarter: −$66M over the past year, against −$61M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BBNX on cash generation, producing positive trailing cash flow while its opponent burns cash.
BBNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.5% | +2M shares |
| 1 year | +6.7% | +2.9M shares |
| 3 years | +8.6% | +3.7M shares |
BBNX has 47M diluted shares, up 6.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BBNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BBNX Net Leverage
BBNX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BBNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.0 | Neutral |
| Stochastic | 29.2 | Neutral |
BBNX's weekly RSI is 49 (neutral) and its Stochastic is 29 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BBNX PE vs Healthcare Sector
BBNX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BBNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.8 | 7.4% below |
| 20 week MA | $17.6 | 6.3% below |
| 50 week MA | $16.4 | 0.5% above |
LLY has stronger trend alignment. BBNX is above 1 of 3 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
BBNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $23.8 | $31.9 | +34% |
| 2026 YTD | $31.9 | $16.5 | -48% |
BBNX has finished every year since 2025 higher, and it's down 48% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BBNX on returns for 2026, with the stronger performance.